Dirk Reuter

A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma

Manfred Westphal, Oliver Heese, Joachim P. Steinbach et al. · European Journal of Cancer · 2015 · 203 citations

Medicine, Oncology, Pharmacology +14

Lipopolysaccharide Activates Caspase-1 (Interleukin-1–Converting Enzyme) in Cultured Monocytic and Endothelial Cells

Ralf R. Schumann, Claus Belka, Dirk Reuter et al. · Blood · 1998 · 157 citations · Full text

Life Sciences, Cell Biology, Immunology +16

Sequencing exons 5 to 8 of the p53 gene by MALDI-TOF mass spectrometry

Dong‐Jing Fu, Kai Tang, Andreas Braun et al. · Nature Biotechnology · 1998 · 134 citations

Life Sciences, Genetics, Molecular Biology +13

Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen inKRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study

Beate Schultheis, Dirk Reuter, M. Ebert et al. · Annals of Oncology · 2017 · 124 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Effects of site-directed mutagenesis of basic residues (Arg 94, Lys 95, Lys 99) of lipopolysaccharide (LPS)-binding protein on binding and transfer of LPS and subsequent immune cell activation

Norbert Lamping, Adolf Hoess, Bo Yu et al. · The Journal of Immunology · 1996 · 123 citations · Full text

Life Sciences, Biochemistry, Immunology +13